Clinical trials: Cardiovascular System
Macular Edema, Central Retinal Vein Occlusion
Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion
The purpose of the study is to evaluate the safety and tolerability of a single administration of FOV2302 (ecallantide) in patients with macular edema associated with central retinal vein occlusion.
- Trial name
- FOV2302 (NCT00969293)
- Testing
- FOV2302 (Ecallantide)
- Where
- 8 sites in France
- Volunteers
- 11 people
- Sponsor
- Fovea Pharmaceuticals SA
Retinal Vein Occlusion, Macular Edema
Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)
This multicenter observational study will assess the efficacy and tolerability of OZURDEX® in clinical practice, and will assess the time at which patients are considered for retreatment.
- Trial name
- NCT01568021
- Testing
- No Intervention
- Where
- 3 sites in Denmark, Norway and 1 more
- Volunteers
- 100 people
- Sponsor
- Allergan
Atrial Fibrillation
Predictive Factors for Successful Outcome After Pulmonary Veins Ablation to Treat Paroxysmal Atrial Fibrillation
Atrial fibrillation is the most common serious abnormal heart rhythm affecting about 2% to 3% of the population, being associated with a 1.5- to 1.9-fold higher risk of death.
- Trial name
- NCT02614521
- Testing
- pulmonary veins ablation's successful outcome
- Where
- Greece
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Familial Hypercholesterolemia - Homozygous
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 2 to <12 years) with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein…
- Trial name
- ORION-19 (NCT06597006)
- Testing
- Inclisiran
- Where
- 19 sites in United States, Austria and 9 more
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Mitral Regurgitation
Cephea Early Feasibility Study
The objective of this study is to evaluate the preliminary safety and effectiveness of the Cephea Mitral Valve System for the treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral…
- Trial name
- NCT05061004
- Testing
- Cephea Mitral Valve System
- Where
- 22 sites in United States, Canada
- Volunteers
- 90 people
- Sponsor
- Abbott Medical Devices
Abdominal Aortic Aneurysm (AAA)
ACZ885 for the Treatment of Abdominal Aortic Aneurysm
This study was designed to assess the safety, tolerability and efficacy of ACZ885 on aneurysmal growth rate in subjects with abdominal aortic aneurysms (AAA).
- Trial name
- AAA (NCT02007252)
- Testing
- ACZ885
- Where
- 9 sites in United States, Denmark and 3 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Study to Evaluate the Safety of UF-KURE-BCMA CAR T-Cells in Advanced Myeloma
The goal of this study is to evaluate the safety of a new type of CAR T-cell, UF-KURE-BCMA, for the treatment of patients with advanced multiple myeloma that has not responded to other therapies.
- Trial name
- NCT07611149
- Testing
- Administration of CAR T-cells at 3 different dose levels
- Volunteers
- 12 people
- Sponsor
- Kure Cells, INC
Coronary Artery Diseases
BIOTRONIK - BIOFLOW-III Registry French Satellite
For the majority of Coronary Artery Disease (CAD) treatment with Percutaneous Transluminal Coronary Angioplasty (PTCA) provides high initial procedure success.
- Trial name
- NCT02273648
- Testing
- Drug Eluting Stent (DES)
- Where
- 50 sites in France
- Volunteers
- 1,000 people
- Sponsor
- Biotronik France
Hypertension
Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resistant hypertension taking between 2 and 5 anti-hypertensive (AHT) medications.
- Trial name
- NCT06153693
- Testing
- lorundrostat Dose 1, lorundrostat Dose 2
- Where
- 184 sites in United States, Australia and 11 more
- Volunteers
- 1,083 people
- Sponsor
- Mineralys Therapeutics Inc.
Heart Disease, Coronary Arterial Disease (CAD)
Feasibility Study of the Supira System in Patients Undergoing HRPCI With Support Beyond the PCI Procedure
The objective of this study is to assess the safety and feasibility of the Supira System in heart failure patients with low LVEF, undergoing HRPCI with use of mechanical circulatory support who may benefit from cardiovascular…
- Conditions
- Heart Disease, Coronary Arterial Disease (CAD), Heart Failure
- Trial name
- NCT07407816
- Testing
- Supira System
- Where
- 2 sites in Georgia
- Volunteers
- 45 people
- Sponsor
- Supira Medical
Vascular Diseases
Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients
The purpose of this study is to determine if the contrast agent is effective and safe in the Magnetic Resonance Imaging (MRI) of vascular diseases in patients of Chinese origin.
- Trial name
- NCT00395733
- Testing
- Gadobutrol (Gadavist, Gadovist, BAY86-4875), Gadopentate dimeglumine (Magnevist, BAY86-4882)
- Where
- 3 sites in China
- Volunteers
- 83 people
- Sponsor
- Bayer
Acute Ischemic Stroke
Single Ascending Dose Safety and Tolerability of NTS-104 Healthy Adults
NTS-104 TRIS will be administered as a single intravenous dose to healthy subjects at doses of 0.8, 4, 8 and 16 mg/kg in 4 Cohorts.
- Trial name
- NCT05547438
- Testing
- NTS-104 TRIS
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- NeuroTrauma Sciences, LLC
Peripheral Artery Disease (PAD)
A Study to Evaluate the Safety and Effectiveness of the FastWave Artero™ Peripheral Intravascular Lithotripsy (IVL) System in Adults With Peripheral Artery Disease (PAD)
The purpose of this clinical study is to learn if the FastWave Artero™ Peripheral Intravascular Lithotripsy (IVL) System is safe and works well to help people with peripheral artery disease (PAD) who have hard, calcium-filled…
- Trial name
- SPARC (NCT07209085)
- Testing
- FastWave Artero™ Peripheral IVL System
- Volunteers
- 110 people
- Sponsor
- FastWave Medical
Peripheral Vascular Disease, Embolism and Thrombosis
Registry of AngioJet Use in the Peripheral Vascular System
The Registry involves the collection of information for research and educational purposes only on the use of AngioJet in the peripheral vascular system.
- Conditions
- Peripheral Vascular Disease, Embolism and Thrombosis, Venous Thrombosis
- Trial name
- PEARLII (NCT01086215)
- Where
- 36 sites in United States, Canada and 3 more
- Volunteers
- 500 people
- Sponsor
- Boston Scientific Corporation
Diabetic Foot, Chronic Foot Ulcer
Randomized Clinical Study Comparing SynPath to Standard of Care in Treatment of Chronic Diabetic Foot Ulcers
The study will evaluate the efficacy of SynPath™, a synthetic dermal matrix, in the treatment of diabetic foot ulcers in subjects with diabetes mellitus versus Standard of Care treatment.
- Conditions
- Diabetic Foot, Chronic Foot Ulcer, Wound Healing, Foot Ulcer
- Trial name
- DFUs (NCT05506215)
- Testing
- SynPath Acellular Dermal Matrix plus Off-loading Device, Wound Dressing composed of 90% collagen and 10% Alginate plus Off-loading Device
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- PolyNovo Biomaterials Pty Ltd.
Heart Failure
Attain Success Clinical Trial
The purpose of the study is to assess lead implant success and complication rate using the Medtronic Attain Family of left-heart leads and delivery catheters.
- Trial name
- NCT00990964
- Testing
- Attain Success Lead
- Where
- 108 sites in United States, Canada and 14 more
- Volunteers
- 2,014 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Complicated Skin and Skin Structure Infections and Bacteremia Including Right-sided Endocarditis
Safety and Efficacy Study of CUBICIN (Daptomycin) Under Conditions of Actual Use
The purpose of this study is to monitor the safety and efficacy of CUBICIN under conditions of actual use in patients who are diagnosed with complicated Skin and Skin Structure infection (cSSI) or Staphylococcus aureus bacteria…
- Trial name
- NCT01219114
- Where
- 5 sites in Philippines
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Hypertension, Abdominal Obesity
Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension
Part 1 determined: aliskiren, amlodipine and angiotensin II concentrations in interstitial fluid of fat and skeletal muscle; aliskiren and angiotensin II concentrations, and renin activity and concentration in fat and skeletal…
- Trial name
- NCT00498433
- Testing
- Aliskiren, Amlodipine
- Where
- 2 sites in Germany
- Volunteers
- 46 people
- Sponsor
- Novartis
Unstable Angina, Myocardial Infarction
Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)
The purpose of this study is to show that, when compared with heparin (enoxaparin or unfractionated heparin) and routine GPIIb/IIIa inhibition (either started upfront or at the time of percutaneous coronary intervention [PCI]…
- Conditions
- Unstable Angina, Myocardial Infarction, Acute Disease
- Trial name
- NCT00093158
- Testing
- Angiomax (bivalirudin) anticoagulant
- Where
- United States
- Volunteers
- 13,800 people
- Sponsor
- The Medicines Company
Aortic Valve Stenosis
A Registry to Evaluate the Direct Flow Medical Transcatheter Aortic Valve System
The purpose of this postmarket Registry is to assess the standard of care and clinical outcomes of the Direct Flow Medical Transcatheter Aortic Valve System used in clinical routine according to the approved commercial…
- Trial name
- DISCOVER (NCT01845285)
- Testing
- Aortic Valve Replacement
- Where
- 2 sites in Germany, Italy
- Volunteers
- 1,000 people
- Sponsor
- Direct Flow Medical, Inc.